Centre Flags Carcinogen Fears On Acidity Medicine Ranitidine, Orders Probe
The Central Drugs Standard Control Organisation (CDSCO) has directed all state and union territory drug regulators to ensure manufacturers of Ranitidine -- a commonly used acidity medicine --monitor NDMA levels, a potentially cancer-causing impurity, in both the active pharmaceutical ingredient (API) and formulations of the drug. The CDSCO has also suggested reducing the shelf life as a precautionary step.
The move comes from the Drugs Controller General of India (DCGI), Dr Rajeev Singh Raghuvanshi, following a recommendation by the Drugs Technical Advisory Board (DTAB) during its 92nd meeting on April 28, 2025.
The Board reviewed a report submitted by an expert committee constituted in December last year to study the impurity concerns around Ranitidine. Based on this, DTAB has called for a larger committee to examine all aspects of the issue, including storage conditions that may contribute to NDMA formation.
In addition, the Board recommended that the Indian Council of Medical Research (ICMR) conduct a study to further assess the long-term safety of Ranitidine in light of NDMA presence.
Manufacturers have now been told to adopt risk-based measures, such as limiting shelf life, modifying storage recommendations, and enhancing NDMA testing protocols across their supply chains.
"Ranitidine falls in the Group 2A carcinogen category, according to the International Agency for Research on Cancer (IARC), which implies that it is a probable human carcinogen. It should not be continued in prescription when there are safer alternatives such as Famotidine and Pantoprazole available," said Dr Abhishek Shankar, Oncologist, AIIMS Delhi.
NDMA is classified as a probable human carcinogen, and its presence in medications has triggered global regulatory scrutiny over recent years. Ranitidine, commonly prescribed for acid reflux and ulcers, was withdrawn from several markets, including the US, after alarmingly high levels of NDMA were found in some samples.
"Ranitidine was commonly prescribed in the past. Its usage has reduced in most metro cities, but it is still prescribed in Tier 1 or 2 cities, particularly at primary healthcare centres. In my knowledge, the drug has been known to have NDMA impurities; the FDA has also ruled out the use of this drug in large doses. The DGCI needs to set prescribed limits for NDMA levels in this drug," said Dr Lohit Chauhan, Gastroenterologist at Max Dwarka.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
6 hours ago
- Time of India
India-UK trade pact to ease market access for domestic medical devices into Britain
New Delhi: The India-UK trade pact has incorporated a mutual recognition agreement framework to facilitate smoother entry of medical devices certified by domestic regulatory agencies into the British market, an official said on Tuesday. The framework will help Indian manufacturers expand market share in the UK vis-a-vis its global competitors like China, Brazil, and Vietnam who face non-preferential duty. "The free trade agreement includes a mutual recognition agreement framework allowing medical devices certified by the Central Drugs Standard Control Organisation (CDSCO) or the Indian Certification of Medical Devices (ICMED) to access the UK market more freely," the official said. Medical devices and instruments will be exported to the UK at zero tariffs, down from the current duty range of 2 per cent to 6 per cent, benefiting Indian manufacturers of surgical and diagnostic equipment. The UK medical devices market was valued at USD 32 billion in 2024 and is projected to reach USD 69 billion by 2035, growing at a CAGR of 7.19 per cent, representing a significant opportunity for Indian medical device manufacturers, the official said. A bilateral regulatory cooperation framework will also be pursued between CDSCO and MHRA (Medicines and Healthcare products Regulatory Agency) potentially taking the form of a Mutual Recognition Agreement (MRA). "The agreement will incorporate provisions for joint inspections, data sharing, harmonization of technical documentation, and training programmes between Indian and UK regulators, which will help build confidence and trust in each other's regulatory frameworks, thereby enhancing market access for our exports," the official said. India remains committed to a fair, balanced, and mutually beneficial agreement and is engaging with the UK to consider pathways for regulatory cooperation, including recognition of CDSCO approvals. Further to prevent routing of third country goods via the UK into India, there are provisions for strong Rules of Origin (RoO) in the comprehensive economic and trade agreement, which define the origin of a product and determine whether it qualifies for preferential tariffs. The combination of rigorous RoO, digital certificate of origin systems, and customs monitoring will ensure that only legitimate products -- made or significantly transformed in the FTA partner -- benefit from tariff concessions.
NDTV
8 hours ago
- NDTV
India-UK Trade Deal To Ease Access For Domestic Medical Devices In Britain
New Delhi: The India-UK trade pact has incorporated a mutual recognition agreement framework to facilitate smoother entry of medical devices certified by domestic regulatory agencies into the British market, an official said on Tuesday. The framework will help Indian manufacturers expand market share in the UK vis-a-vis its global competitors like China, Brazil, and Vietnam who face non-preferential duty. "The free trade agreement includes a mutual recognition agreement framework allowing medical devices certified by the Central Drugs Standard Control Organisation (CDSCO) or the Indian Certification of Medical Devices (ICMED) to access the UK market more freely," the official said. Medical devices and instruments will be exported to the UK at zero tariffs, down from the current duty range of 2 per cent to 6 per cent, benefiting Indian manufacturers of surgical and diagnostic equipment. The UK medical devices market was valued at USD 32 billion in 2024 and is projected to reach USD 69 billion by 2035, growing at a CAGR of 7.19 per cent, representing a significant opportunity for Indian medical device manufacturers, the official said. A bilateral regulatory cooperation framework will also be pursued between CDSCO and MHRA (Medicines and Healthcare products Regulatory Agency) potentially taking the form of a Mutual Recognition Agreement (MRA). "The agreement will incorporate provisions for joint inspections, data sharing, harmonization of technical documentation, and training programmes between Indian and UK regulators, which will help build confidence and trust in each other's regulatory frameworks, thereby enhancing market access for our exports," the official said. India remains committed to a fair, balanced, and mutually beneficial agreement and is engaging with the UK to consider pathways for regulatory cooperation, including recognition of CDSCO approvals. Further to prevent routing of third country goods via the UK into India, there are provisions for strong Rules of Origin (RoO) in the comprehensive economic and trade agreement, which define the origin of a product and determine whether it qualifies for preferential tariffs. The combination of rigorous RoO, digital certificate of origin systems, and customs monitoring will ensure that only legitimate products -- made or significantly transformed in the FTA partner -- benefit from tariff concessions.
Hans India
10 hours ago
- Hans India
Why tobacco-style warnings on alcohol bottles can aid fight against cancer
New Delhi: Adopting tobacco-style warning labels on alcohol bottles can be a key measure to prevent the rising burden of cancer in India, said experts on Tuesday. A recent paper, published in the journal Frontiers in Public Health, called for strong, evidence-based warning labels on alcohol products, building on India's success with tobacco warnings. Alcohol, like tobacco, is a proven carcinogen linked to several cancers, including liver, breast and colon, yet awareness remains low. 'Cancer warning labels on alcohol bottles are a low-cost, high-impact intervention that can raise awareness, influence consumption habits, and prevent long-term health harm,' lead author Dr Abhishek Shankar, Assistant Professor, Department of Radiation Oncology at All India Institute of Medical Sciences, Delhi, told IANS. 'With India having one of the fastest-growing alcohol markets and the largest adolescent population globally, adopting such preventive measures is not just necessary but urgent to protect our youth and reduce the nation's growing burden of alcohol-related cancers,' the oncologist added. Cancer cases in India have seen a steep rise, with data from the 2012 to 2022 period suggesting a 36 per cent uptick in incidence (1.01 million−1.38 million). Data from GLOBOCAN 2022 showed about 1.41 million new cancer cases in India, with a five-year prevalence of around 3.25 million and a total cancer mortality of 916,827 cases. The alcohol attributable fraction for cancer and age-standardised rate per 100,000 in India are 4.7 per cent and 4.8, respectively, according to the GLOBOCAN 2020 data. 'Alcohol consumption in India is rising at an alarming pace, particularly among adolescents and young adults, making it a silent driver of preventable cancers. Evidence now confirms there is no safe level of alcohol use when it comes to cancer risk, with links to cancers of the colon, breast, liver, oral cavity, and more,' Shankar said. 'Among preventable diseases and deaths, alcohol-related conditions rank high. It raises the risk of many types of cancer and also liver cirrhosis -- all of which are expensive and cumbersome to treat,' added Dr Rajeev Jayadevan, Chairman, Scientific Committee, IMA Cochin. The expert also called out against glorifying the use of alcohol in movies. 'Unfortunately, our movie culture glorifies alcohol use, with younger viewers wanting to emulate movie characters despite statutory warnings. There is also rampant misinformation circulating on social media claiming the health benefits of alcohol, almost all of which have been proven wrong. Still, many people wrongly believe it is good for the heart. Therefore, it is important to include clear health-related labels,' Jayadevan told IANS. Meanwhile, studies have linked alcohol consumption with more than 20 types of cancers. The most common cancers linked to alcohol are of the mouth, throat, foodpipe, stomach, colon, rectum, and pancreas. It also causes cancers of the breast in women and prostate in males.. According to experts, chronic alcohol consumption weakens the immune system, reducing its capacity to identify and destroy cancerous cells. 'India successfully demonstrated the power of pictorial warnings on tobacco in shifting behaviors and saving lives. It is time we apply the same public health tool to alcohol. With rising alcohol use, especially among youth, it's time to act proactively to prevent avoidable cancers and save lives,' Shankar told IANS.
